Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 FCF Margin % is -3.46% as of Dec. 2025. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, PuraPharm ranks better than 65.07% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PuraPharm's Free Cash Flow for the
six
months ended in Dec. 2025 was HK$-5.7 Mil. PuraPharm's Revenue for the
six
months ended in Dec. 2025 was HK$163.8 Mil. Therefore, PuraPharm's FCF Margin % for the quarter that ended in Dec. 2025 was -3.46%.
The historical data trend for PuraPharm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PuraPharm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a FCF Margin % of -3.46% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PuraPharm and its competitors. According to the industry distribution chart, PuraPharm ranks #335 out of 959 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is PuraPharm's FCF Margin % too high?
PuraPharm's current FCF Margin % is -3.46%. Based on the distribution chart, PuraPharm ranks #335 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #335 out of 959 companies for FCF Margin %. This puts PuraPharm in the upper half of its industry. The industry median FCF Margin % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.40, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current FCF Margin % is -3.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current FCF Margin % is -3.46%. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current FCF Margin % is -3.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
FCF Margin %: -3.46%
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
